574729-41-2

Upstream product

• 574729-40-1 4-tert-butoxycarbonylamino-2-(3,4-dichlorophenyl)-butyric acid methyl ester 

Downstream Products

• 887128-65-6 [3-(3,4-dichloro-phenyl)-3-(4-oxo-3,4-dihydro-quinazolin-7-ylcarbamoyl) propyl]-carbamic acid tert-butyl ester 
• 574729-27-4 3-Amino-5-[4-tert-butoxycarbonylamino-2-(3,4-dichloro-phenyl)-butyrylamino]-indazole-1-carboxylic acid tert-butyl ester 

Relevant academic research and scientific papers

AKT PROTEIN KINASE INHIBITORS

The present invention provides compounds, including resolved enantiomers, diastereomers, solvates and pharmaceutically acceptable salts thereof, comprising the Formula: A-L-CR where CR is a cyclical core group, L is a linking group and A is as defined herein. Also provided are methods of using the compounds of this invention as AKT protein kinase inhibitors and for the treatment of hyperproliferative diseases such as cancer.

Indazole compounds useful as protein kinase inhibitors

The present invention provides compounds of formula I: or a pharmaceutically acceptable derivative thereof, wherein R1, R2, V1, V2, and V3 are as described in the specification. These compounds are inhibitors of protein kinase, particularly inhibitors of AKT, PKA, PDK1, p70S6K, or ROCK kinase, mammalian protein kinases involved in proliferative and neurodegenerative disorders. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of utilizing those compositions in the treatment of various disorders.